Edition:
India

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

9.15USD
22 Jun 2018
Change (% chg)

$-0.32 (-3.38%)
Prev Close
$9.47
Open
$9.47
Day's High
$9.50
Day's Low
$9.08
Volume
1,213,886
Avg. Vol
48,785
52-wk High
$15.38
52-wk Low
$7.41

Chart for

About

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the... (more)

Overall

Beta: 1.75
Market Cap(Mil.): $187.24
Shares Outstanding(Mil.): 13.28
Dividend: 10.55
Yield (%): --

Financials

BRIEF-Merrimack Pharmaceuticals Reports Q1 Operating Loss Per Share Of $1.33

* THREE CLINICAL READOUTS EXPECTED IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES

08 May 2018

BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results

* MERRIMACK PROVIDES BUSINESS UPDATE AND REPORTS 2017 FINANCIAL RESULTS

12 Mar 2018

BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer

* MERRIMACK STRENGTHENS SHERLOC STUDY OF MM-121 IN NON-SMALL CELL LUNG CANCER

12 Mar 2018

BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121

* MERRIMACK - ‍ DOSED FIRST PATIENT IN RANDOMIZED PHASE 2 CLINICAL STUDY OF MM-121 IN PATIENTS WITH POST-MENOPAUSAL METASTATIC BREAST CANCER​

26 Feb 2018

Competitors

Earnings vs. Estimates